CC
REGN icon

Corton Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Corton Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-209
Closed -$220K – 596
2024
Q3 		$220K Buy
+209
New +$233K 0.11% 334
2024
Q2 		– Sell
-1,302
Closed -$1.25M – 710
2024
Q1 		$1.25M Sell
1,302
-284
-18% -$270K 0.46% 15
2023
Q4 		$1.39M Buy
1,586
+238
+18% +$196K 0.44% 20
2023
Q3 		$1.11M Sell
1,348
-409
-23% -$321K 0.56% 18
2023
Q2 		$1.26M Buy
1,757
+1,020
+138% +$786K 0.59% 9
2023
Q1 		$606K Buy
+737
New +$556K 0.42% 35
2022
Q2 		– Sell
-795
Closed -$555K – 483
2022
Q1 		$555K Buy
+795
New +$503K 0.24% 93

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Corton Capital's REGN Position: Q4 2024 in Review

Corton Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 209 shares — an estimated $220K sold.

Corton Capital first reported a position in REGN in Q1 2022 and held it in 7 quarters. The position peaked at $1.39M in Q4 2023. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Corton Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 209 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $220K.
  • Corton Capital first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Corton Capital's Regeneron Pharmaceuticals position peaked at $1.39M in Q4 2023.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.